ExploreWatchlistsPricing
  1. JP-listed companies
  2. SymBio Pharmaceuticals Limited
  3. Financials
  4. Gross margin (%)

SymBio Pharmaceuticals Limited (4582)

Market cap
¥6.6B
P/E ratio
-1.3x
Symbiopharm develops drugs for rare diseases in cancer and viral infections, focusing on compounds with proven human efficacy to reduce development risks.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross margin (%) YoY (%)
Dec 31, 202572.4-5.13%
Dec 31, 202476.4-3.23%
Dec 31, 202378.9+3.92%
Dec 31, 202275.9+8.02%
Dec 31, 202170.3+142.24%
Dec 31, 202029-4.77%
Dec 31, 201930.5-0.35%
Dec 31, 201830.6+2.13%
Dec 31, 201729.9-21.58%
Dec 31, 201638.2+26.61%
Dec 31, 201530.2+11.95%
Dec 31, 201426.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat